---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-146806"
form_type: "8-K/A"
ticker: "TBPH"
cik: "0001583107"
company_name: "Theravance Biopharma, Inc."
filed_at: "2021-12-06T23:59:59+00:00"
generated_at: "2026-06-28T03:31:25.703749+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "medium"
source: SEC EDGAR
---

# Theravance Biopharma enters consulting agreement with departing SVP; equity awards to vest

## Summary
- Vijay Sabesan, SVP Technical Operations, left effective Nov 30, 2021 as previously reported.
- On Nov 30, 2021, Company and Sabesan entered a consulting agreement to facilitate transition.
- Certain outstanding equity awards will vest under the consulting agreement; no dollar amount disclosed.

## SEC filing metadata
- accession: 0001104659-21-146806
- form_type: 8-K/A
- ticker: TBPH
- cik: 0001583107
- company_name: Theravance Biopharma, Inc.
- filed_at: 2021-12-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: medium
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583107/000110465921146806/0001104659-21-146806-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583107/000110465921146806/tm2134621d1_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-146806
- JSON: https://secwatch.observer/filing/0001104659-21-146806.json
- Plain text: https://secwatch.observer/filing/0001104659-21-146806.txt

## Key facts
- Executive change
  Vijay Sabesan departed as other_named_officer at Theravance Biopharma, Inc..
  - Action: departed
  source text: On November 30, 2021, the Company and Mr. Sabesan entered into a consulting agreement to facilitate the transition of activities following Mr. Sabesan’s departure, pursuant to which certain outstanding equity awards will vest.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1583107/000110465921146806/0001104659-21-146806-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.